Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
These results indicated that HER2-low status did not have a significant association with ORR and OS, but it may have a worse impact on PFS in patients who received mixed-line or first-line CDK4/6i and ET, as well as mixed-line or post-line palbociclib plus ET.
Authors
- Wei-Yun Xu
- Lin-Yu Xia (ORCID: https://orcid.org/0000-0003-4802-2359)
- Qing-Lin Hu
- Xuchen Cao (ORCID: https://orcid.org/0000-0001-8829-4530)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Mianyang Central Hospital (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.3389/fonc.2024.1413674
- Citations
- 7
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 2.93